National Institutes of Health: Cholangiocarcinoma trials

The registry lists 42 Cholangiocarcinoma studies with National Institutes of Health as lead sponsor. 5 are open to participants now and 20 have results posted.

Phase 1 10Phase 2 31No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingNCT07715903Phase 1
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaRecruitingNCT05286814Phase 2
• Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingNCT04645160Phase 1/2
• Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruitingNCT01915225
• Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisCompletedNCT05185947Phase 2Results posted
• Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerActive, not recruitingNCT04941287Phase 2Results posted
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).TerminatedNCT04566133Phase 2Results posted
• Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the LiverActive, not recruitingNCT04175912Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsCompletedNCT04034238Phase 1Results posted
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingNCT03878095Phase 2Results posted
• Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompletedNCT03801915Phase 2Results posted
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results posted
• Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerCompletedNCT03201458Phase 2Results posted
• Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary CancersTerminatedNCT01229111Phase 2Results posted
• Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT01093222Phase 2Results posted
• Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryCompletedNCT00553332Phase 2Results posted
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTerminatedNCT00478140Phase 2Results posted
• Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCompletedNCT00356889Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingNCT05564403Phase 2
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerCompletedNCT04145141
• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingNCT04068194Phase 1/2
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract CancerCompletedNCT00559598
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1/2
• Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or LymphomasCompletedNCT00019513Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1